Developing cell based therapeutic products.
Cure Disease Like Never Before
DEACT technology ensures stable supply of stem cell derived immune cells, synergistic actions among immune cells; ability to overcome immune evasion and immunosuppression of cancer cells.
Sleeping Beauty Platform :
The first clinical tested non-viral gene transfer technology will cut the production time from weeks to a couple of days; It is uniquely suitable for generating combinatory products targeting multiple cancer antigens such as cancer neoantigens.
Through uniquely designed hinge and intracellular domains, HiSAFE technology improves the safety of CAR T cells and enhances the function of these cells by negating the immune suppression property of cell surface receptor.
Exosome Engineering Platform:
Genetically Engineered exosomes capable of large scale production and delivery of various payloads.
SB-CAR for blood malignancies
Retro/Lenti-TCR for solid tumors
Retro-TCR for blood malignancies
Retro-COMBO for solid tumors
Oncolytic virus with controllable cytokines for solid tumor Stage- Preclinical/IND.